ELN

[cumulina]

While I'm waiting for ELN to start the next nice advance, I borrowed this from the yahoo-board. Would be a pity not to share it with you.

Not all on those boards is trash. 


Recommend this Post - This post has 88 recommendations
Vindication: the Stealth Upgrade
by: truthe_sayer
Long-Term Sentiment: Buy 12/17/05 02:23 pm
Msg: 851553 of 851553

This has been a most telling week for Elan. And interspersed with the flash, the tumult, the bombast is yet another example from that den of duplicity, that canyon or corruption, that grotto of greed we know and hate called Wall Street.

The phenomena is the Stealth Upgrade. But it is that in name only for the noble savages, the shrewd iconoclasts, the astute mavens, the important nobodies that populate this message board. How stupid that the shifty, the snarky, the devious types in the investment community think they can fool us?

The Stealth Upgrade constitutes a change in sentiment or recommendation or directive from: SELL to HOLD. It is without a doubt the most telling, most devastating, most compelling upgrade that can be issued. For, it is poorly cloaked message that the analyst senses that a train, a tsunami, a tornado is coming on the upside and it is time to get out of the way. It is a face saving admission that the analysis was wrong. It is a capitulation that the analyst is desperately forced to make to salvage their reputation, their career, their livelihood from an adverse avalanche of favorable facts about to swamp them – even while he or she fervently hopes it escapes notice. It's the ultimate CYA.

And so a few weeks ago this sorry, unseemly and disgusting spectre presented itself from the minions of mendacity as a change in investment rating on Elan from AG Edwards from Sell to Hold.

And this week we encountered an even more clever sleight of hand from Mad Money. For all his chair throwing, spittle laced invective and ADHD mannerisms, Mr. Cramer is not an idiot. He has discovered it is easier to make money in entertainment than in investment. And for weeks upon months he has mindlessly piled on Elan along with all the other nabobs of negativism. Safety in numbers. Bad news sells papers. Bad mouthing builds audiences. Mr. Cramer has literally worn out his "sell, sell, sell" and growl-of-the-bear sound FX buttons when callers inquired of Elan.

But last week something interesting happened. And you had to look past his hyperbolic verbiage to see it. But when the subject of Elan came up this time he pushed the "Ring the Register" sound FX button. Now, taking profits is at least arguably NOT exactly the same as "sell, sell, sell." But perhaps his button aim was amiss.

But this week something even MORE interesting happened. Parse Mr. Cramer's actions (not his marginally understandable words) and you will note he pushed the "Don't buy, don't buy" sound FX button. That is, absolutely without equivocation, a change from "Sell, sell, sell". It was a Stealth Upgrade of monumental proportions. Even entertainer Cramer realizes his specious stock picking reputation is under threat from Elan.

As far as Elan goes it is just another piece of the puzzle falling inexorably, inevitably, irrevocably, irretrievably into place.

The Bearish Ship of Fools is foundering... and the rats are clawing all over each other to leave any way they can – while furiously, desperately, trying not to draw attention to themselves. It's a lemmings' headlong rush into the sea.

The Stealth Upgrade is one of their favorite, hackneyed, smarmy, unimaginative and tired-out tools. Expect more in the coming weeks. Why do they think these will fool any of us?

They won't. Because, for Elan, the third time will truly be the charm.

[Prfsr Hal]

I bought at 8.39 and more at 11.  I sense a return to the mid 20's and beyond.
Prfsr Hal

[bourkeco]

Glad to see that not all on this site are ignoring ELN. I got lucky and found this one @ 5.75 and am still long. I think we will see $25-30 by mid year, Just a gut feeling nothing to back it up but there is more in ELN's bag now.

[cumulina]

Does anyone know of any news causing this movement today?

On the yahoo-board there are rumours about good news regarding the alzheimers-drug, but I haven't been able to find anything.

Not complaining, though!

[calven]

ELN making a symmetrical triangle...

[basonista]

Looks like we have a breakout of the symmetrical triangle on above average volume.  No news that I can find to trigger this. 

[basonista]

Wow!  Just broke through solid resistance around $16 with continued strong volume!  Next strong resistance at recent high of $16.83.

[basonista]

Updated chart.  No news yet on Tysabri return.  We'll see if this move from Friday can continue.

[basonista]

Hits a new 52 week high on increasing volume. 

[basonista]

Another 52 week high on increasing volume.  Potential consolidation ahead although MACD has some room to run.   

[kslifka]

Sorry Basonista...I noticed you're posting ELN as well.  I've been positing on the Stock trading board.  Been in and out of ELN since it tanked over a year ago.  It's looking good here with the huge gap to fill up to $25.


Cheers,
kslifka

[basonista]

Ahh, I see that you have been posting on ELN.  Sometimes the search doesn't pull up all of the threads.

ELN was what got me into investing in stocks last year.  I saw it tank, did a little research and thought it would bounce back eventually and that Tysabri had a good chance of returning to market.  If only I had kept those shares I bought at less than $4!

[cumulina]

I rushed back to ELN yesterday.

Bought after hours at 13.31

Some strange confusion about fake news etc. really caused a stir.

If you can't stomach the yahoo message boards, then the good posters have all moved to

http://www1.investorvillage.com/smbd.asp?mb=160&pt=m

So have I!!!

Cheers!

[cumulina]

...And "something" was going on.
I wonder what kind of movement we will see on ELN today 



24 July 2006
Biogen Idec and Elan Announce Availability of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis
CAMBRIDGE, Mass. and DUBLIN, Ireland--(BUSINESS WIRE)--July 24, 2006--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the commercial availability of TYSABRI® (natalizumab) for the treatment of relapsing forms of multiple sclerosis (MS) in the U.S. As previously announced, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for the reintroduction of TYSABRI as a monotherapy treatment for relapsing forms of MS to slow the progression of disability and reduce the frequency of clinical relapses.

The FDA granted approval for reintroduction based on the review of TYSABRI clinical trial data; revised labeling with enhanced safety warnings; and a risk management plan (TOUCH Prescribing Program) designed to inform physicians and patients of the benefits and risks of TYSABRI treatment and minimize potential risk of progressive multifocal leukoencephalopathy (PML). Because of the increased risk of PML, TYSABRI is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate MS therapies.

Under the TOUCH Prescribing Program, only prescribers, infusion centers and pharmacies associated with infusion centers registered in the TOUCH program are able to prescribe, infuse or distribute TYSABRI. Elan has contracted with a single distributor, ICS, a division of AmerisourceBergen Specialty Group, and 12 specialty pharmacies: Caremark, CuraScript, PharmaCare, PrecisionRx Specialty Solutions, Medmark, BioScrip, McKesson Specialty, Option Care, Cigna Tel-Drug Specialty Pharmacy, Aetna Specialty Pharmacy, Prescription Solutions, and Accredo NovaFactor. ICS and the 12 specialty pharmacies have been trained on the TOUCH Prescribing Program and are obligated to follow the requirements of the program in order to purchase and distribute TYSABRI to authorized infusion sites and central pharmacies.

In addition, following the recent approval by the European Commission, the companies have introduced TYSABRI in several countries in Europe.

About TYSABRI

Two-year data from the AFFIRM monotherapy trial showed that treatment with TYSABRI reduced the risk of disability progression by 42% (p<0.001), the primary endpoint of the study, and led to a 67% reduction (p<0.001) in the annualized relapse rate compared to placebo. TYSABRI treatment also resulted in sustained and statistically significant reductions in brain lesion activity as measured by MRI. The two-year data from the SENTINEL add-on trial also demonstrated that treatment with TYSABRI in addition to AVONEX(R) (Interferon beta-1a) had a significant effect on disability progression, relapse rate and brain MRI disease activity compared to AVONEX alone.

TYSABRI increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Three cases of PML occurred in clinical trial patients who were concomitantly exposed to immunomodulators (interferon beta in the patients with MS) or were immunocompromised due to recent treatment with immunosuppressants (e.g., azathioprine in the patient with Crohn's disease). Two of the cases were observed in 1,869 patients with MS treated for a median of 120 weeks. A third case of PML occurred among 1,043 patients with Crohn's disease after the patient received eight doses. The number of cases is too few and the number of patients treated too small to reliably conclude that the risk of PML is lower in patients treated with TYSABRI alone than in patients who are receiving other drugs that decrease immune function or who are otherwise immunocompromised. Healthcare professionals should monitor patients on TYSABRI for any new signs or symptoms that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML.

TYSABRI is contraindicated in patients who have or have had PML or with known hypersensitivity to TYSABRI or any of its components. In Phase III placebo-controlled trials of TYSABRI in MS, the overall incidence and rate of other infections were balanced between TYSABRI-treated patients and controls. Herpes infections were slightly more common in patients treated with TYSABRI. Commonly reported infections with TYSABRI included urinary tract infections, lower respiratory tract infections, gastroenteritis and vaginitis. Serious opportunistic and other atypical infections have been observed in TYSABRI-treated patients, some of these patients were receiving concurrent immunosuppressants.

The incidence and rate of other serious and common adverse events in clinical trials were similarly balanced between treatment groups. Serious events that occurred in TYSABRI-treated patients included hypersensitivity reactions (e.g., anaphylaxis), depression and gallstones. Appendicitis was more common in patients receiving TYSABRI with AVONEX. Common adverse events reported in TYSABRI-treated patients include infusion reactions, headache, fatigue, joint and limb pain, abdominal discomfort, diarrhea and rash.

For more information about TYSABRI please visit www.biogenidec.com, www.elan.com, or www.tysabri.com.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit www.elan.com.